DexCom, Inc. $DXCM Shares Sold by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its stake in DexCom, Inc. by 46.7%, selling 13,372 shares, leaving it with 15,271 shares worth approximately $1,043,000 as of the last quarter.
• DexCom reported a quarterly earnings per share (EPS) of $0.48, surpassing analysts' expectations of $0.45, and generated revenue of $1.16 billion for the quarter.
• Several hedge funds increased their holdings in DexCom, with Golden State Wealth Management raising its stake by 211.2% in the first quarter of this year.

Tema Etfs LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 46.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,271 shares of the medical device company's stock after selling 13,372 shares during the quarter. Tema Etfs LLC's holdings in DexCom were worth $1,043,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Horizon Investments LLC boosted its holdings in DexCom by 2.2% in the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock valued at $383,000 after purchasing an additional 123 shares in the last quarter. Nia Impact Advisors LLC lifted its stake in DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after buying an additional 140 shares during the last quarter. Wedbush Securities Inc. lifted its stake in DexCom by 1.2% in the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock valued at $899,000 after buying an additional 157 shares during the last quarter. Argonautica Private Wealth Management Inc. lifted its stake in DexCom by 3.2% in the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock valued at $407,000 after buying an additional 182 shares during the last quarter. Finally, Trivium Point Advisory LLC lifted its stake in DexCom by 6.1% in the first quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company's stock valued at $236,000 after buying an additional 200 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ:DXCM traded up $0.26 during trading hours on Monday, hitting $75.34. The company's stock had a trading volume of 2,921,932 shares, compared to its average volume of 4,070,578. The business's 50-day moving average is $82.25 and its two-hundred day moving average is $79.41. The company has a market capitalization of $29.54 billion, a PE ratio of 52.32, a PEG ratio of 1.58 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom's revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DXCM shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $106.00 price objective on shares of DexCom in a research note on Friday, August 1st. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Mizuho upped their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Truist Financial assumed coverage on DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Finally, Raymond James Financial upped their price target on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $99.89.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the sale, the executive vice president directly owned 106,689 shares in the company, valued at $9,494,254.11. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,722 shares of company stock worth $1,306,131. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.